Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $11,561.94 in Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 234 shares of the company’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $49.41, for a total value of $11,561.94. Following the transaction, the insider now directly owns 79,831 shares in the company, valued at approximately $3,944,449.71. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Friday, June 14th, Dennis Cho sold 95 shares of Twist Bioscience stock. The shares were sold at an average price of $51.04, for a total value of $4,848.80.
• On Thursday, June 6th, Dennis Cho sold 276 shares of Twist Bioscience stock. The stock was sold at an average price of $51.33, for a total value of $14,167.08.

Twist Bioscience Price Performance

Shares of TWST stock opened at $46.47 on Thursday. The stock has a market capitalization of $2.71 billion, a PE ratio of -13.83 and a beta of 1.78. Twist Bioscience Co. has a 1-year low of $14.42 and a 1-year high of $55.26. The business has a 50-day moving average of $43.03 and a 200 day moving average of $38.05.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.05. The company had revenue of $75.30 million during the quarter, compared to analysts’ expectations of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. Twist Bioscience’s quarterly revenue was up 25.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.06) EPS. Analysts anticipate that Twist Bioscience Co. will post -3.08 EPS for the current year.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors have recently bought and sold shares of TWST. American International Group Inc. lifted its holdings in Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after buying an additional 213 shares during the period. D.A. Davidson & CO. lifted its holdings in Twist Bioscience by 3.4% in the 4th quarter. D.A. Davidson & CO. now owns 16,774 shares of the company’s stock worth $618,000 after buying an additional 554 shares during the period. EdgeRock Capital LLC purchased a new stake in Twist Bioscience in the 4th quarter worth approximately $30,000. Swiss National Bank lifted its holdings in Twist Bioscience by 0.8% in the 1st quarter. Swiss National Bank now owns 114,000 shares of the company’s stock worth $3,911,000 after buying an additional 900 shares during the period. Finally, ProShare Advisors LLC lifted its holdings in Twist Bioscience by 10.2% in the 1st quarter. ProShare Advisors LLC now owns 14,444 shares of the company’s stock worth $496,000 after buying an additional 1,336 shares during the period.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Barclays increased their price objective on Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Guggenheim assumed coverage on Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price objective on the stock. TD Cowen increased their price objective on Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Evercore ISI upped their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Finally, Scotiabank upped their target price on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research note on Monday, May 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Buy” and an average target price of $46.63.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.